Xiaodong Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaodong Cheng has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Jinyun Ma
Institute of Clinical Immunology, Yueyang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
13 shared publicationsYuanhua Wang
Institute of Clinical Immunology, Yue‐Yang Hospital of Integrative Medicine Shanghai University of Traditional Chinese Medicine Shanghai China
12 shared publicationsGuiqing Ding
Institute of Clinical Immunology, Yueyang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
10 shared publicationsQijin Lu
Institute of Clinical Immunology, Yue‐Yang Hospital of Integrative Medicine Shanghai University of Traditional Chinese Medicine Shanghai China
8 shared publicationsXi Qiao
Institute of Clinical Immunology, Yue‐Yang Hospital of Integrative Medicine Shanghai University of Traditional Chinese Medicine Shanghai China
7 shared publicationsYan Zhao
Institute of Clinical Immunology, Yue-yang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China
6 shared publications
Latest Publications
- Open Access
- 14 April 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (4) , e71797
Astragalus Polysaccharides Induce Immunogenic Cell Death in Melanoma: A Mechanism Mediated by cGAS / STING Activation via Intratumoral Microbiota Modulation
Astragalus polysaccharides (APS) exhibits potent immunomodulatory properties, yet its interplay with intratumoral microbiota in driving antitumor immunity remains elusive. Herein, we demonstrate that APS suppresses melanoma growth and prolongs survival by inducing immunogenic cell death (ICD) via the cGAS‐STING pathway. Inhibition of cGAS‐STING abrogated APS efficacy. Notably, depletion of intratumoral microbiota using antibiotics blunted APS‐mediated cGAS‐STING activation and immune responses, confirming a microbiota‐dependent mechanism. 5R 16S rRNA sequencing identified Pseudomonas enrichment as a distinct signature of APS treatment. Crucially, administration of Pseudomonas sterile supernatant was sufficient to activate cGAS‐STING signaling, induce ICD, and inhibit tumor growth in microbiota‐depleted mice. We propose that APS acts as an upstream modulator that enriches Pseudomonas, creating a microenvironment where bacterial secretions trigger the cGAS‐STING pathway to induce ICD. These findings provide a novel theoretical basis for microbiota‐targeted immunotherapies.
- 14 April 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (4) , e71797
Open AccessAstragalus Polysaccharides Induce Immunogenic Cell Death in Melanoma: A Mechanism Mediated by cGAS / STING Activation via Intratumoral Microbiota Modulation
Astragalus polysaccharides (APS) exhibits potent immunomodulatory properties, yet its interplay with intratumoral microbiota in driving antitumor immunity remains elusive. Herein, we demonstrate that APS suppresses melanoma growth and prolongs survival by inducing immunogenic cell death (ICD) via the cGAS‐STING pathway. Inhibition of cGAS‐STING abrogated APS efficacy. Notably, depletion of intratumoral microbiota using antibiotics blunted APS‐mediated cGAS‐STING activation and immune responses, confirming a microbiota‐dependent mechanism. 5R 16S rRNA sequencing identified Pseudomonas enrichment as a distinct signature of APS treatment. Crucially, administration of Pseudomonas sterile supernatant was sufficient to activate cGAS‐STING signaling, induce ICD, and inhibit tumor growth in microbiota‐depleted mice. We propose that APS acts as an upstream modulator that enriches Pseudomonas, creating a microenvironment where bacterial secretions trigger the cGAS‐STING pathway to induce ICD. These findings provide a novel theoretical basis for microbiota‐targeted immunotherapies.
- 25 February 2026
- Published by Elsevier in Brain Research
- Vol. 1880, 150234
Astragalus polysaccharide ameliorates neuroinflammation in EAE mice by modulating microglial autophagy to reduce lipid droplet accumulation
- 25 February 2026
- Published by Elsevier in Brain Research
- Vol. 1880, 150234
Astragalus polysaccharide ameliorates neuroinflammation in EAE mice by modulating microglial autophagy to reduce lipid droplet accumulation
- Open Access
- 22 May 2025
- Published by Elsevier in Journal of Integrative Medicine
- Vol. 23 (4) , 382-389
Integrating traditional Chinese medicine constitutions into insomnia management: Findings from a cross-sectional study
- 22 May 2025
- Published by Elsevier in Journal of Integrative Medicine
- Vol. 23 (4) , 382-389
Open AccessIntegrating traditional Chinese medicine constitutions into insomnia management: Findings from a cross-sectional study
- Open Access
- 13 December 2024
- Published by Elsevier in Brain Research Bulletin
- Vol. 220, 111171
Th17/Treg balance is regulated during the suppression of experimental autoimmune encephalomyelitis treated by Astragalus polysaccharides via the microbiota-gut-brain axis
- 13 December 2024
- Published by Elsevier in Brain Research Bulletin
- Vol. 220, 111171
Open AccessTh17/Treg balance is regulated during the suppression of experimental autoimmune encephalomyelitis treated by Astragalus polysaccharides via the microbiota-gut-brain axis
- 1 November 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 985, 177090
Demyelination in cuprizone mice is ameliorated by calycosin mediated through astrocyte Nrf2 signaling pathway
- 1 November 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 985, 177090
Demyelination in cuprizone mice is ameliorated by calycosin mediated through astrocyte Nrf2 signaling pathway
- 12 October 2024
- Published by Elsevier in Brain Research
- Vol. 1845, 149275
Microglia-astrocyte crosstalk is regulated by Astragalus polysaccharides mediated through suppression of Sema4D-PlexinB2 signaling in experimental autoimmune encephalomyelitis
- 12 October 2024
- Published by Elsevier in Brain Research
- Vol. 1845, 149275
Microglia-astrocyte crosstalk is regulated by Astragalus polysaccharides mediated through suppression of Sema4D-PlexinB2 signaling in experimental autoimmune encephalomyelitis
- Open Access
- 9 October 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 180, 117521
Disruption of blood-brain barrier and endothelial-to-mesenchymal transition are attenuated by Astragalus polysaccharides mediated through upregulation of ETS1 expression in experimental autoimmune encephalomyelitis
- 9 October 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 180, 117521
Open AccessDisruption of blood-brain barrier and endothelial-to-mesenchymal transition are attenuated by Astragalus polysaccharides mediated through upregulation of ETS1 expression in experimental autoimmune encephalomyelitis
- 3 September 2024
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 117 (1)
CD8+T cell infiltration–associated barrier function of brain endothelial cells is enhanced by astragalus polysaccharides via inhibiting the PI3K/AKT signaling pathway
Pathogenic CD8+T cells play an essential role in neuroinflammation and neural injury, which leads to the progression of inflammatory neurological disorders. Thus, blocking the infiltration of CD8+T cells is necessary for the treatment of neuroinflammatory diseases. Our previous study demonstrated that astragalus polysaccharide (APS) could significantly reduce the infiltration of CD8+T cells in experimental autoimmune encephalomyelitis mice. However, the mechanism by which APS suppresses CD8+T cell infiltration remains elusive. In this study, we further found that APS could reduce the CD8+T cell infiltration in experimental autoimmune encephalomyelitis and lipopolysaccharide (LPS)-induced neuroinflammatory model. Furthermore, we established the mouse brain endothelial cell (bEnd.3) inflammatory injury model by interleukin-1β or LPS in vitro. The results showed that APS treatment downregulated the expression of vascular cell adhesion molecule1 to decrease the adhesion of CD8+T cells to bEnd.3 cells. APS also upregulated the expression of zonula occludens-1 and vascular endothelial cadherin to reduce the transendothelial migration of CD8+T cells. The PI3K/AKT signaling pathway might mediate this protective effect of APS on bEnd.3 cells against inflammatory injury. In addition, we demonstrated the protective effect of APS on the integrity of brain endothelial cells in an LPS-induced neuroinflammatory model. In summary, our results indicate that APS can reduce peripheral CD8+T cell infiltration via enhancing the barrier function of brain endothelial cells; it may be a potential for the prevention of neuroinflammatory diseases.
- 3 September 2024
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 117 (1)
CD8+T cell infiltration–associated barrier function of brain endothelial cells is enhanced by astragalus polysaccharides via inhibiting the PI3K/AKT signaling pathway
Pathogenic CD8+T cells play an essential role in neuroinflammation and neural injury, which leads to the progression of inflammatory neurological disorders. Thus, blocking the infiltration of CD8+T cells is necessary for the treatment of neuroinflammatory diseases. Our previous study demonstrated that astragalus polysaccharide (APS) could significantly reduce the infiltration of CD8+T cells in experimental autoimmune encephalomyelitis mice. However, the mechanism by which APS suppresses CD8+T cell infiltration remains elusive. In this study, we further found that APS could reduce the CD8+T cell infiltration in experimental autoimmune encephalomyelitis and lipopolysaccharide (LPS)-induced neuroinflammatory model. Furthermore, we established the mouse brain endothelial cell (bEnd.3) inflammatory injury model by interleukin-1β or LPS in vitro. The results showed that APS treatment downregulated the expression of vascular cell adhesion molecule1 to decrease the adhesion of CD8+T cells to bEnd.3 cells. APS also upregulated the expression of zonula occludens-1 and vascular endothelial cadherin to reduce the transendothelial migration of CD8+T cells. The PI3K/AKT signaling pathway might mediate this protective effect of APS on bEnd.3 cells against inflammatory injury. In addition, we demonstrated the protective effect of APS on the integrity of brain endothelial cells in an LPS-induced neuroinflammatory model. In summary, our results indicate that APS can reduce peripheral CD8+T cell infiltration via enhancing the barrier function of brain endothelial cells; it may be a potential for the prevention of neuroinflammatory diseases.
- Open Access
- 21 August 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-11
Modulation of PD-L1 by Astragalus polysaccharide attenuates the induction of melanoma stem cell properties and overcomes immune evasion
Melanoma is a highly aggressive form of skin cancer. The existence of cancer stem cells (CSCs) and tumor immune evasion are two major causes of melanoma progression, but no effective treatment has been found at present. Astragalus polysaccharide (APS) is a principal active component derived from Astragalus membranaceus, showing anti-tumor effects in various tumors including melanoma. However, the underlying mechanism is still unclear. The regulation of APS on self-renewal ability and CSC markers expression in melanoma stem cells (MSCs) was measured by tumor sphere formation and tumorigenicity assays, RT-qPCR, and western blot. Flow cytometry was conducted to evaluate the activation of immune system by APS in melanoma mice. Further, the mechanism was explored based on PD-L1 overexpression and knock-down B16 cells. APS attenuated the tumor sphere formation of MSCs in vitro as well as the tumorigenicity in vivo. It also decreased the expression of CD133, BMI1 and CD47. Based on the PD-L1 overexpression and knock-down B16 cells, it was confirmed that APS inhibited the induction of MSCs by down-regulating PD-L1 expression. Meanwhile, APS increased the infiltration of CD4+ and CD8+T cells in tumor tissues because of its inhibitory effect on PD-L1. APS inhibited MSC induction and overcame tumor immune evasion through reducing PD-L1 expression. This study provided compelling evidence that APS could be a prospective therapeutic agent for treating melanoma.
- 21 August 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-11
Open AccessModulation of PD-L1 by Astragalus polysaccharide attenuates the induction of melanoma stem cell properties and overcomes immune evasion
Melanoma is a highly aggressive form of skin cancer. The existence of cancer stem cells (CSCs) and tumor immune evasion are two major causes of melanoma progression, but no effective treatment has been found at present. Astragalus polysaccharide (APS) is a principal active component derived from Astragalus membranaceus, showing anti-tumor effects in various tumors including melanoma. However, the underlying mechanism is still unclear. The regulation of APS on self-renewal ability and CSC markers expression in melanoma stem cells (MSCs) was measured by tumor sphere formation and tumorigenicity assays, RT-qPCR, and western blot. Flow cytometry was conducted to evaluate the activation of immune system by APS in melanoma mice. Further, the mechanism was explored based on PD-L1 overexpression and knock-down B16 cells. APS attenuated the tumor sphere formation of MSCs in vitro as well as the tumorigenicity in vivo. It also decreased the expression of CD133, BMI1 and CD47. Based on the PD-L1 overexpression and knock-down B16 cells, it was confirmed that APS inhibited the induction of MSCs by down-regulating PD-L1 expression. Meanwhile, APS increased the infiltration of CD4+ and CD8+T cells in tumor tissues because of its inhibitory effect on PD-L1. APS inhibited MSC induction and overcame tumor immune evasion through reducing PD-L1 expression. This study provided compelling evidence that APS could be a prospective therapeutic agent for treating melanoma.
- 23 February 2024
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (4) , 215-228
Reciprocal Relationship Between Cancer Stem Cells and Myeloid-Derived Suppressor Cells: Implications for Tumor Progression and Therapeutic Strategies
Recently, there has been an increased focus on cancer stem cells (CSCs) due to their resilience, making them difficult to eradicate. This resilience often leads to tumor recurrence and metastasis. ... Plain language summary Cancer stem cells (CSCs) are a kind of tumor cell. These cells are hard to kill but contribute to tumor progression and metastasis. Myeloid-derived suppressor cells (MDSCs) e...
- 23 February 2024
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (4) , 215-228
Reciprocal Relationship Between Cancer Stem Cells and Myeloid-Derived Suppressor Cells: Implications for Tumor Progression and Therapeutic Strategies
Recently, there has been an increased focus on cancer stem cells (CSCs) due to their resilience, making them difficult to eradicate. This resilience often leads to tumor recurrence and metastasis. ... Plain language summary Cancer stem cells (CSCs) are a kind of tumor cell. These cells are hard to kill but contribute to tumor progression and metastasis. Myeloid-derived suppressor cells (MDSCs) e...